Inventor
PABLO UMANA
Inventor
CH
Overview
Patents· 47 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides33%
A61KPreparations for medical, dental or toiletry purposes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C12NMicroorganisms or enzymes4%
C12YEnzymes1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
12,565,530Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody202612,473,373Bispecific antibody molecules binding to CD3 and EGFRvIII202512,441,812Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules202512,391,757Bispecific antibodies specific for PD1 and TIM3202512,286,486Anti-FAP antibodies and methods of use202512,281,153Combination therapy with targeted 4-1BB (CD137) agonists202512,275,794Bispecific antigen binding molecules comprising anti-FAP clone 212202512,258,371Stabilized immunoglobulin domains202512,240,911Bispecific antibodies specific for OX40202512,215,155Antibodies binding to CD3 and CD19202512,202,870Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof202512,145,994Bispecific antigen binding molecules capable of specific binding to CD40 and to fap202412,139,553T cell activating bispecific antigen binding molecules202412,103,982T cell activating bispecific antigen binding molecules202412,098,213Antibodies binding to HLA-A2/WT1202412,065,478HER2-targeting antigen binding molecules comprising 4-1BBL202412,049,515Agonistic CD28 antigen binding molecules targeting Her2202412,023,368Immunoconjugates202411,993,642Trivalent, bispecific antibodies202411,987,632Antibodies binding to HLA-A2/MAGE-A4202411,952,421Bispecific antibodies against CD3EPSILON and ROR1202411,865,082Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1202411,827,711Antibodies binding to NKG2D202311,787,873Bispecific HER2 antibodies and methods of use202311,780,919Bispecific antigen binding molecules targeting OX40 and FAP202311,780,920Antibodies binding to CD3 and CD19202311,718,680Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists202311,672,858Bispecific antibody molecules binding to CD3 and TYRP-1202311,639,394Bispecific antigen binding molecule for a costimulatory TNF receptor202311,639,397Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use202311,613,587Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists202311,608,376Tumor-targeted agonistic CD28 antigen binding molecules202311,591,397Bispecific antibody molecules binding to CD3 and EGFRvIII202311,459,404Bispecific T cell activating antigen binding molecules202211,453,722Bispecific antigen binding molecule for a costimulatory TNF receptor202211,447,558Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9202211,413,331Immunoconjugates202211,365,232Interleukin-2 fusion proteins and uses thereof202211,340,234Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody202211,332,545Anti-FAP antibodies and methods of use202211,306,154Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer202211,267,903Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer202211,242,390Protease-activated T cell bispecific molecules202211,242,396Bispecific antigen binding molecules comprising anti-FAP clone 212202211,214,622Antibodies specific for DR5 and methods of use202211,192,957Antibodies binding to HLA-A2/WT1202111,149,083Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to HOFFMANN LA ROCHE (40)· patent assignee history
2021Patents assigned to HOFFMANN—LA ROCHE INC (1)· patent assignee history
2021–2026Based in CH· patent location history
2022–2025Patents assigned to ROCHE GLYCART AG (6)· patent assignee history
2022Patents assigned to HOFMANN LA ROCHE INC (1)· patent assignee history
2024Patents assigned to BRISTOL MYERS SQUIBB CO (1)· patent assignee history
2024Based in DE· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HOFFMANN LA ROCHE | 40 | 2021–2026 |
| ROCHE GLYCART AG | 6 | 2022–2025 |
| BRISTOL MYERS SQUIBB CO | 1 | 2024 |
| HOFFMANN—LA ROCHE INC | 1 | 2021 |
| HOFMANN LA ROCHE INC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| CH | 46 | 2021–2026 |
| DE | 1 | 2024 |